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A cetaminophen (N-acetyl-p-aminophenol, APAP, paracetamol) is the most commonly used drug for the treatment of pain and fever around the world. Liver injury secondary to acetaminophen overdose results in hepatocellular necrosis, which may lead to acute liver failure (ALF) and death. 1, 2 Acetaminophen toxicity is a leading cause of ALF in industrialized nations, accounting for 45% of ALF cases in the United States 2 and 40% of cases in Great Britain. 3 An early and accurate diagnosis of acetaminophen overdose is important for treatment to be successful. During the early stages of toxicity, diagnosis is based on a combination of medical history (use of acetaminophencontaining products) and detection of an increased acetaminophen level in the peripheral circulation. 4 However, ALF patients by definition have impaired mental status and/or may not be forthcoming about their ingestion of acetaminophen. In addition, serum acetaminophen concentrations frequently are low or undetectable in patients with bona fide acetaminophen hepatotoxicity owing to the lag between ingestion and clinical presentation. 2 The Rumack 4,5 nomogram initially was designed for the assessment of single time point ingestions, and is applicable for the initial 18 to 24 hours after the overdose. However, limitations of the nomogram include the short elimination half-life of acetaminophen in the peripheral circulation, inaccuracy of patient history regarding the time of acetaminophen exposure, and the large proportion of patients with acetaminophen overdose who report chronic/repetitive dosing of multiple products containing acetaminophen.
After large-dose acetaminophen ingestions, hepatic glutathione is depleted and the capacity of the conjugation pathways is exceeded, resulting in a shift in metabolism to the cytochrome P450-mediated (predominantly CYP2E1, CYP1A2, and CYP3A4) generation of the highly reactive and toxic intermediate metabolite N-acetyl-p-benzoquinone imine (NAPQI). 6, 7 NAPQI rapidly binds with the amino acid cysteine in cellular proteins to form acetaminophenprotein adducts (3-[cysteine-S-yl] acetaminophen), which subsequently are released into the peripheral circulation during toxicity as a result of hepatocyte lysis. 8 Quantitation of adducts in sera or plasma through high-pressure liquid chromatography with electrochemical detection (HPLC-EC) has been shown in both experimental models and clinical studies. [9] [10] [11] [12] However, this assay requires complex analytic equipment and highly trained laboratory personnel.
The median elimination half-life of acetaminophen protein adducts in adults with ALF was found previously to be 42 hours (range, 22.6-61.2 h), 12 and exceeded that noted for the parent drug acetaminophen (median, 5.4 h; range, 0.8-119.7 h) reported in a study of 112 adults treated with N-acetylcysteine (NAC) for acetaminophen overdose. 13 As a result, detection of serum acetaminophen-protein adducts offers an appealing diagnostic approach, particularly in patients who may present more than 12 to 24 hours after ingestion. Previous studies have shown that sera from 18% to 19% of cases of indeterminate ALF contained quantities of acetaminophen-protein adducts that were higher than the toxic threshold, strongly implicating acetaminophen as the cause of the ALF and supporting the diagnostic potential of the assay. 10, 12, 14, 15 Herein, we report a proof-of-concept study of a rapid, point-of-care lateral flow assay, AcetaSTAT, to detect serum acetaminophen protein adducts in patients with liver injury. The results of the AcetaSTAT assay were compared with the gold standard HPLC-EC assay, causality review diagnosis, and diagnosis as determined by expert opinion post hoc analysis.
Methods

Study Design
Seven clinical sites within the Acute Liver Failure Study Group (ALFSG) participated in a multicenter study designed to test the performance of AcetaSTAT in patients with the diagnosis of ALF and acute liver injury (ALI). ALF was defined as follows: (1) presence of coagulopathy (international normalized ratio for prothrombin time [INR] ! 1.5), (2) evidence of hepatic encephalopathy, and (3) presentation within 26 weeks of illness onset without evidence of previous liver disease, using previously established criteria.
2 ALI was limited to subjects without encephalopathy and defined by the following criteria: for acetaminophen cases, INR of 2.0 or greater from a 2-week or shorter illness and an alanine aminotransferase (ALT) level of 10Â the upper limit of normal or greater; for nonacetaminophen cases, an illness of 26 weeks or less with a bilirubin level of 3.0 mg/dL or greater, ALT level at least 10Â the upper limit of normal, accompanied by an INR of 2.0 or greater. Control subjects, recruited from the University of Arkansas for Medical Sciences, had no exposure to acetaminophen in the 14-day period before participation in the study. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by institutional review boards of all participating sites.
Study participants were patients enrolled consecutively in the ALFSG standard registry for collection of data and biosamples (ClinTrials: NCT00518440). Each study subject or next of kin was asked to consent separately to the additional AcetaSTAT study. After informed consent, a single blood sample (2 mL) was obtained from study subjects and then centrifuged and aliquoted into 2 serum samples within 30 minutes of collection. One aliquot was frozen at -70 C for future determination of acetaminophen protein adducts by HPLC-EC. The other aliquot was used for testing of AcetaSTAT as described later. Clinical data collected included sex, age, weight, ALT value on the day of testing, peak ALT value during the 7-day ALFSG registry participation, acetaminophen concentration, INR, and 21-day outcome (survival, death/no transplant, transplant, or lost to follow-up evaluation). The site investigator's initial etiologic diagnosis was followed by a causality review process performed by the ALFSG causality committee, in which a standard algorithm was applied and data were reviewed by 2 additional investigators. 16 Both the site investigator and the causality review committee were blinded to AcetaSTAT and HPLC-EC results. Four discordant cases were evaluated further in a post hoc analysis with AcetaSTAT and HPLC-EC adduct determinations unblinded. Sample processing and testing times also were recorded.
AcetaSTAT
AcetaSTAT is a competitive immunoassay configured as a lateral-flow immunochromatographic assay that detects 3-(cysteine-S-yl) acetaminophen protein adducts (3-cys-A or adduct) in patient serum. AcetaSTAT (Supplementary Figure 1) was manufactured by Bioassay Works (Ijamsville, MD) using rabbit serum containing anti-3-cys-A specific antibody, 17,18 synthetic 3-cys-A adduct for immobilization at the test band, and serum standards containing known adduct levels. The assay contains a control band to verify assay integrity. The amount of antibody used for each AcetaSTAT assay was titrated to saturation by a threshold amount of adduct, such that antibody bound at or above the threshold amount of adduct in the sample was not available to bind at the test band. The amount of antibody used in the AcetaSTAT assay corresponded to 3.2 ng IgG with specificity for the 3-(cysteine-S-yl) acetaminophen protein adduct. The assay was optimized such that assay inhibition adduct levels of 1 nmol/mL. Drugs commonly combined with acetaminophen in prescription products were spiked into control and adduct serum at 10Â the high therapeutic level; no drug interference was detected (Supplementary Figure 2) . Serum samples were obtained from experimental control subjects (n ¼ 5) who received therapeutic doses of acetaminophen (1 g orally every 12 h). Samples obtained 4 hours after the second dose of acetaminophen were negative by the AcetaSTAT test (Supplementary Table 1 ).
The threshold of approximately 1.0 nmol adducts/mL serum was based on our previous publications, showing high sensitivity and specificity for adduct greater than 1.0 nmol/mL measured by HPLC-EC in subjects with a history of acetaminophen ingestion and ALT levels greater than 1000 IU/L. 2, 15 A standard curve ( Figure 1 ) was prepared by spiking healthy control serum with synthetic adduct prepared by modifying bovine serum albumin with the reactive metabolite NAPQI. AcetaSTAT results were interpreted using a table top reader (Reader 250; MaTEST, Mössingen, Germany), customized for AcetaSTAT and hereafter referred to as the test reader. The test reader contains a sensitive camera and image analysis software to capture test band and control band density, which are recorded as arbitrary reflectance units. Because of the competitive nature of immunoassay, test band amplitudes were related inversely to adduct concentration and a reading of 1200 or less was considered positive and indicated the presence of clinically significant levels of acetaminophen-protein adducts. 12, 14 Test readers were calibrated using prepared standards and quality control cassettes were run before each AcetaSTAT test at the study site. Data archived at the site by the reader included site identification, tester, research subject identification number, quality control cassette identification, date and time of reading, a digital image of the test result, test band and control band intensity, pass/ fail reading for the control band, software version, and serial number of the reader. Printed reports were saved after each test and used as the source for data entry.
Testing Procedures
Each study site appointed a tester who completed training on testing procedures. Test results remained confidential and were not released to the treating physician or medical staff. Serum samples were gelfiltered using Zeba desalt spin columns (Thermo Fischer Scientific, Inc, Waltham, MA), then mixed with a lyophilized aliquot of rabbit anti-acetaminophen-protein adduct antisera and applied to the sample application port of AcetaSTAT. After the testing of each subject sample, the data collection report was sealed in a coded envelope to maintain blinding of test results.
High-Performance Liquid Chromatography With Electrochemical Detection Determination of Acetaminophen-Protein Adducts
Serum samples were analyzed within 6 months of collection by HPLC-EC as described previously.
9,14 Samples were gel-filtered and hydrolyzed to release acetaminophen cysteine from acetaminophen-protein adducts. After protein precipitation and extraction, samples were injected on the HPLC-EC system and resolved on a 150-mm C 18 column (Symmetry; Waters, Milford, MA) using a mobile phase containing 8% vol/vol methanol and 50 mmol/L sodium acetate (pH 4.8), and detected using a coulometric electrochemical detector (Esa Corp, Chelmsford, MA). 9 The final acetaminophen-protein adduct values were reported as nmol APAP-cys/mL serum. Receiver operator curve analysis established that a threshold adduct level of 1 nmol/mL or greater adduct-derived acetaminophen cysteine corresponded to serious acetaminophen toxicity as defined by an increase of ALT level greater than 1000 IU/L in patients with known acetaminophen ALF (sensitivity, 97%; specificity, 95%).
12,14
Data Management
Clinical and laboratory data were collected by study personnel at each site. All data were stored and managed using Research Electronic Data Capture, 19 hosted by the Translational Research Institute at the University of Arkansas for Medical Sciences (National Center for Research Resources/National Institutes of Health grant 1 UL1 RR02988). To maintain patient confidentiality and security of study data, only key study personnel were granted access to the study's Research Electronic Data Capture project. Study personnel at a particular site were assigned to that site's data access group. Access to study data was brokered by data access groups; each site's ability to edit and/or retrieve records was restricted to records created by the users within that site's data access group. Collected data were monitored weekly by the statistical team; data exportation was limited to the principal investigators and the statistical team. The analytic data set was de-identified and all personal health information was removed during the analysis stage. After completion of study enrollment, all authors had access to the study data and reviewed and approved the final manuscript.
Statistical Analysis
Differences between groups were analyzed using the 
Results
Clinical and Laboratory Data
A total of 81 subjects participated in the study, including 62 subjects from the 7 ALFSG study sites and 19 control subjects from the University of Arkansas for Medical Sciences site. Table 1 provides summary data for controls, 29 subjects diagnosed with nonacetaminophen ALF, and 33 subjects considered to have acetaminopheninduced, further stratified by whether they had ALI (15) or ALF (18) , as determined by the causality review committee. No significant differences were detected for age or sex among the 3 subject groups. The 21-day survival rates were significantly higher in the acetaminophen compared with the nonacetaminophen subjects (78% vs 56%; P ¼ .02), consistent with previous studies. 2 The diagnoses of the 29 nonacetaminophen subjects were acute ischemic liver injury (9), idiosyncratic nonacetaminophen drug-induced acute liver injury (8), viral hepatitis (3), indeterminate (6), autoimmune hepatitis (2), and Wilson disease (1) .
Of the 33 subjects who had acetaminophen-induced ALI or ALF, only 10 had known ingestion times. Among these 10 subjects, the median time of acetaminophen ingestion relative to blood sampling for the AcetaSTAT assay was 3.0 days (minimum, maximum, 1.1, 6.1 days). Notably, all of these ingestion times were beyond the 24-hour time window during which the Rumack nomogram is considered applicable.
Serum Acetaminophen-Protein Adduct Testing
The median time to complete the AcetaSTAT test was 27 minutes (minimum, maximum, 25, 45 min). As shown in Table 1 , results of AcetaSTAT testing and HPLC-EC for acetaminophen-protein adducts clearly differed among the controls, acetaminophen subjects, and nonacetaminophen subjects. The results of AcetaSTAT testing discriminated between acetaminophen and nonacetaminophen ALI/ALF (median test band amplitudes, 584 and 3678, respectively; P < .001). In addition, AcetaSTAT results differed according to the severity of acetaminophen liver injury (Table 2) as stratified by a diagnosis of ALI or ALF. Figure 2 shows the relationship between AcetaSTAT and HPLC-EC results in aliquots of the same serum sample for all study subjects, identified by diagnostic category in color-coded symbols. AcetaSTAT results are plotted as the reciprocal of test band intensity or amplitude. Because of the nature of the competitive immunoassay, test band amplitude was related inversely to the level of acetaminophen-protein adducts in the subject sample. Thus, acetaminophen cases with increased adduct levels had low or inhibited reactions at the test band.
Overall, there was consensus between the diagnosis of acetaminophen etiology and a positive AcetaSTAT test (test band 1200) or the diagnosis of nonacetaminophen etiology and a negative AcetaSTAT test (test band > 1200) in 77 of 81 subjects (95.1%). Furthermore, there was agreement between the AcetaSTAT-positive results and HPLC-EC adduct determinations of 1.0 nmol or greater APAP-cys/mL or AcetaSTAT negative results and HPLC-EC results on less than 1.0 nmol APAP-cys/mL in 76 of 81 subjects (93.8%).
The overall performance characteristics for Aceta-STAT compared with diagnosis were as follows: sensitivity, 100%; specificity, 86.2%; positive predictive value, 89.2%; and negative predictive value, 100% (Table 3) .
As defined by lack of consensus between causality review diagnosis and the AcetaSTAT result, there were 4 cases in which the diagnosis indicated nonacetaminophen etiology, but the AcetaSTAT result was positive. In 3 cases (Table 4) , both AcetaSTAT and HPLC-EC results were in agreement, showing adduct levels near or greater than the toxicity threshold, suggesting toxic exposure to acetaminophen. The fourth case had a causality review diagnosis of autoimmune hepatitis and was negative by HPLC-EC. Details of these 4 subjects are provided in Table 4 and in the case histories provided in the Supplementary Materials and Methods section.
Discussion
The primary objective of this study was to compare the results of the rapid assay AcetaSTAT, performed at remote study sites, with the established HPLC-EC method performed at a central laboratory for determining acetaminophen-protein adducts in patients with ALF/ALI. Assay performance characteristics for AcetaSTAT were highly favorable and the study results showed the feasibility of a point-of-care assay to diagnose acetaminophen-related ALF/ALI rapidly and accurately. AcetaSTAT takes approximately 27 minutes to complete, is remarkably easy to perform, and does not require specialized equipment or training. In comparison, the HPLC-EC method for acetaminophen-protein adduct detection requires trained personnel, specialized equipment, and the results typically are not available for 2 to 3 days. The acetaminophen-protein adduct is a unique product of acetaminophen metabolism; increased levels of acetaminophen-protein adducts only occur as a consequence of acetaminophen toxicity and remain increased in serum long after the parent compound acetaminophen has been metabolized. 6, 7 Other existing laboratory tests, such as ALT, aspartate aminotransferase, bilirubin, and INR, are not specific to acetaminophen liver injury. The classic pattern of very high aminotransferase levels and low bilirubin levels is remarkably uniform in acetaminophen injury, but also is mimicked by ischemic liver injury, which, in the absence of frank shock or cardiac arrest, can be difficult to recognize. 14, 20 In the present study, agreement of results between AcetaSTAT and HPLC-EC was observed in all but one instance (subject 50), with the HPLC-EC result being consonant with the causality review diagnosis. In this patient with autoimmune hepatitis, it is possible that high levels of IgG may have interfered with the rapid test results. However, AcetaSTAT results were consistent with the diagnosis in other study subjects (n ¼ 2) determined to have autoimmune hepatitis. For the remaining 3 disparate cases, both AcetaSTAT and HPLC-EC detected adducts and were concordant, but were at odds with the causality review diagnosis. In all 3 patients, the biochemical profile at presentation with a high ALT level and a low total bilirubin level was perfectly compatible with acetaminophen-induced liver injury, but the site investigator did not diagnose acetaminophen overdose either owing to denial or minimization of acetaminophen ingestion or the possibility of an unrecognized ischemic episode. All 3 cases that were considered either indeterminate or ischemia were determined to be highly likely/definite acetaminophen on subsequent post hoc analysis. As noted in the Methods section, the results of HPLC-EC and AcetaSTAT adduct determinations were not provided to the causality review committee, but were considered in the post hoc analysis. Uncertainty will always surround instances in which the patient either does not recall or minimizes (or denies) NOTE. The AcetSTAT cut-off point was defined as the test band intensity (1200) corresponding to HPLC-EC determination of APAP-protein adducts > 1.0 nmol/mL.
any acetaminophen ingestion (subjects 78 and 66), and also will be present when the biochemical profile is that of hyperacute injury and ischemia is suggested as a possible diagnosis by additional supporting data (subject 61). Based on post hoc analysis, we submit that all 3 cases were very likely acetaminophen toxicity, supported by the positive HPLC-EC and AcetaSTAT assays.
Determining the correct etiology of ALF early in the presentation is important for a variety of reasons. First, treatment with NAC is most effective if given as soon as possible and thus a positive AcetaSTAT assay can guide treatment decisions at the point of care in the Emergency Department. In addition, for research studies such as genome-wide association or other studies examining disease phenotype, the correct assignment of etiology of ALF is essential.
In the current study, detection of threshold levels of acetaminophen-protein adduct, either by AcetaSTAT or HPLC-EC, reliably identified acetaminophen etiology based on a single determination and regardless of other clinical chemistry measures in 77 of 81 cases (95.1%). In contrast, none of the measures traditionally used by clinicians in making a determination of acetaminophen etiology were particularly useful for confirming acetaminophen as a cause of ALF or ALI. For example, a detectable serum acetaminophen (parent compound) level was present in 3 of the 29 nonacetaminophen ALF/ ALI cases (false positive) at study enrollment, and in only 17 of the 33 bona fide acetaminophen ALF/ALI cases, yielding 16 false-negative instances. The observation that serum acetaminophen was not detected in 16 of the 33 acetaminophen ALF/ALI subjects (48.5%) confirms that detection of acetaminophen cannot be relied on as a means to diagnose acetaminophen toxicity, as recently confirmed in a larger series from the ALFSG. 21 Predefined laboratory cut-off points such as high aminotransferase or INR levels also were not effective in making the determination of acetaminophen etiology (data not shown). In addition, a detectable serum acetaminophen level is indicative only of acetaminophen exposure, not necessarily acetaminophen-induced hepatotoxicity, but often is useful in the right setting as supportive information. Collectively, these data indicate that adduct assays (either AcetaSTAT or HPLC-EC) are more specific and accurate in diagnosing acetaminophen as the etiology of ALF/ALI, and in some instances surpass expert clinicians, providing biochemical confirmation beyond history, acetaminophen levels, and the characteristic hyperacute increase of hepatic transaminase levels.
Our study had several limitations. The major limitation of the AcetaSTAT test is that it was designed to provide a categoric positive or negative result, corresponding to approximately a 1-nmol/mL adduct threshold that has been associated with serious liver toxicity, defined as an ALT level greater than 1000 IU/L. Thus, continuous data below the threshold, such as that previously observed in mild cases of acetaminophen toxicity or with therapeutic exposures to acetaminophen, [22] [23] [24] [25] would not be detected by AcetaSTAT. Thus, it is possible that the selected threshold 9 may limit the usefulness of AcetaSTAT for sorting out ALI of multiple etiologies that may include acetaminophen and for identifying an overdose patient presenting very early, who does not yet have significant injury. 26 Despite this limitation, the data indicated a very good correlation of AcetaSTAT results with the causality review diagnosis.
Determination of the specific etiology of ALF/ALI is essential in the acute liver injury setting because this knowledge contributes to treatment decisions and referral patterns. Despite numerous reports that acetaminophen toxicity is a major contributor to ALF/ALI, treatment with the antidote NAC is not initiated universally in all patients with ALF/ALI.
14 AcetaSTAT, as compared with the previously established HPLC-EC assay, can provide rapid results to direct treatment decisions to the treating physician at the point of clinical care. Because the survival rate of acetaminophen ALF is more favorable than that of other causes of ALF, assay results could impact future physician referral patterns and reduce medical costs associated with additional tests to determine the etiology of liver injury. Although the current AcetaSTAT prototype requires a reader for interpretation of test band results, future modifications to the assay design and sensitivity threshold could eliminate the reader requirement and further simplify the existing assay.
In conclusion, a rapid test for serum acetaminophen-protein adducts (AcetaSTAT) showed excellent sensitivity and specificity to identify patients with acetaminophen-induced liver injury in this proof-ofconcept study. The test may help guide treatment 
